Myovant Sciences Ltd (MYOV)

[stockguard]

State Street Corp grew its holdings in Myovant Sciences Ltd (NYSE:MYOV) by 70.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,500 shares of the company’s stock after buying an additional 23,800 shares during the quarter. State Street Corp owned 0.06% of Myovant Sciences worth $299,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Victory Capital Management Inc. boosted its stake in shares of Myovant Sciences by 169.8% in the second quarter. Victory Capital Management Inc. now owns 2,272,013 shares of the company’s stock worth $20,562,000 after acquiring an additional 1,429,770 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Myovant Sciences by 33.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,086,893 shares of the company’s stock worth $9,836,000 after acquiring an additional 274,745 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Myovant Sciences in the second quarter worth approximately $7,733,000. Rock Springs Capital Management LP boosted its stake in shares of Myovant Sciences by 29.5% in the second quarter. Rock Springs Capital Management LP now owns 450,000 shares of the company’s stock worth $4,073,000 after acquiring an additional 102,500 shares during the last quarter. Finally, First Manhattan Co. boosted its stake in shares of Myovant Sciences by 2,146.6% in the second quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock worth $3,620,000 after acquiring an additional 382,195 shares during the last quarter. Institutional investors and hedge funds own 39.23% of the company’s stock.


NYSE MYOV opened at $14.06 on Tuesday. Myovant Sciences Ltd has a fifty-two week low of $4.14 and a fifty-two week high of $26.02. The company has a debt-to-equity ratio of 5.88, a current ratio of 2.79 and a quick ratio of 2.79. The stock’s fifty day moving average is $15.87 and its two-hundred day moving average is $9.23.
Myovant Sciences (NYSE:MYOV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.07). On average, research analysts anticipate that Myovant Sciences Ltd will post -3.29 earnings per share for the current year.
A number of analysts have recently issued reports on the company. Zacks Investment Research lowered Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, November 12th. ValuEngine lowered Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. JMP Securities reissued a “buy” rating and set a $34.00 price objective on shares of Myovant Sciences in a research note on Tuesday, November 19th. Finally, Goldman Sachs Group reissued a “buy” rating and set a $20.00 price objective (up previously from $18.00) on shares of Myovant Sciences in a research note on Tuesday, November 19th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $23.46.

In other Myovant Sciences news, insider Frank Karbe sold 19,701 shares of Myovant Sciences stock in a transaction on Monday, December 30th. The stock was sold at an average price of $15.55, for a total value of $306,350.55. Following the sale, the insider now owns 43,324 shares in the company, valued at $673,688.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Sciences Ltd. Roivant bought 179,193 shares of Myovant Sciences stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $18.44 per share, for a total transaction of $3,304,318.92. Following the transaction, the insider now directly owns 44,623,079 shares of the company’s stock, valued at $822,849,576.76. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,046,099 shares of company stock worth $61,228,506 and sold 41,304 shares worth $644,009. 3.68% of the stock is owned by insiders.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

https://rivertonroll.com/news/2020/01/14/myovant-sciences-ltd-nysemyov-shares-acquired-by-state-street-corp-updated.html